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The Elongin complex was originally identiﬁed as a positive regulator of RNA polymerase II
and is composed of a transcriptionally active subunit (A) and two regulatory subunits (B and
C).The Elongin BC complex enhances the transcriptional activity of Elongin A. “Classical”
SOCS box-containing proteins interact with the Elongin BC complex and have ubiquitin
ligase activity.They also interact with the scaffold protein Cullin (Cul) and the RING domain
protein Rbx and thereby are members of the Cullin RING ligase (CRL) superfamily. The
Elongin BC complex acts as an adaptor connecting Cul and SOCS box proteins. Recently,
it was demonstrated that classical SOCS box proteins can be further divided into two
groups, Cul2- and Cul5-type proteins. The classical SOCS box-containing protein pVHL is
now classiﬁed as a Cul2-type protein. The Elongin BC complex containing CRL family is
now considered two distinct protein assemblies, which play an important role in regulating
a variety of cellular processes such as tumorigenesis, signal transduction, cell motility, and
differentiation.
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INTRODUCTION
Polyubiquitin-mediated protein degradation plays an important
role in the elimination of short-lived regulatory proteins (Peters,
1998),includingthosethatcontributetothecellcycle,cellularsig-
nalinginresponsetoenvironmentalstressorextracellularligands,
morphogenesis, secretion, DNA repair, and organelle biogenesis
(Hershko and Ciechanover,1998). The system responsible for the
attachment of ubiquitin to the target protein consists of several
components that act in concert (Hershko and Ciechanover, 1992;
Scheffner et al., 1995), including a ubiquitin-activating enzyme
(E1), a ubiquitin-conjugating enzyme (E2), and a ubiquitin–
protein isopeptide ligase (E3). E3 is believed to be the component
of the ubiquitin conjugation system that is most directly respon-
sible for substrate recognition (Scheffner et al., 1995). Based on
structural similarity, E3 enzymes have been classiﬁed into three
families: the HECT (homologous to E6-AP COOH terminus)
family (Huibregtse et al., 1995; Hershko and Ciechanover, 1998),
the RING ﬁnger-containing protein family (Lorick et al., 1999;
Freemont, 2000; Joazeiro and Weissman, 2000), and the U box
family (Aravind and Koonin, 2000; Hatakeyama et al., 2001; Cyr
et al., 2002). The S phase kinase-associated protein 1 (Skp1)–
Cullin 1 (Cul1)–F box protein (SCF) family is a member of
the RING ﬁnger-containing ubiquitin ligase family (Lipkowitz
and Weissman, 2011). Cul1 is a scaffold protein and assembles
multiple proteins into complexes, which include a small RING
ﬁnger protein (Rbx1),an adaptor protein (Skp1),and a substrate-
targeting protein (F box protein). Substrate recognition by the
RING ﬁnger-containing ubiquitin ligase family is modulated by
post-translational modiﬁcations of the target substrate, includ-
ing phosphorylation, glycosylation, and sumoylation (Lipkowitz
and Weissman, 2011). One substrate can be polyubiquitinated
by different ubiquitin ligases and vice versa. The Elongin B and
C–Cul2 or Cul5–SOCS box protein (ECS) family also belongs to
the Cullin RING ligase (CRL) superfamily (Kile et al., 2002). SCF
and ECS ubiquitin ligases have structural similarities in that both
contain Rbx1 or Rbx2 as a RING ﬁnger protein and Cul1,Cul2,or
Cul5 as a scaffold protein (Kile et al., 2002; Kamura et al., 2004).
Although Skp1 is used as an adaptor protein in the SCF com-
plex, the Elongin B and C complex is used as an adaptor in the
ECS complex. Here, we review the Cul2- or Cul5-containing ECS
ubiquitin ligase family, about which, compared to SCF ubiquitin
ligases, relatively little is known.
THE ELONGIN COMPLEX
The Elongin complex is a positive regulator of RNA polymerase II
(pol II) and increases the rate of elongation by suppressing tran-
sient pausing along the DNA template (Bradsher et al., 1993a,b).
The Elongin complex is composed of a transcriptionally active A
subunit and two regulatory subunits,B and C (Garrettetal.,1994,
1995; Aso et al., 1995). Elongin B and C form the Elongin BC
complex, which enhances the transcriptional activity of Elongin
A. Since Elongin B and C partially resemble ubiquitin and Skp1
(an adaptor of SCF-type ubiquitin ligases),respectively (Bai et al.,
1996), they are able to serve as components of protein complexes
with functions other than transcriptional regulation. For exam-
ple,they were found to be components of the von Hippel–Lindau
(VHL)tumorsuppressorcomplex,whichisalsoknownastheECS




by germline mutations in the VHL tumor suppressor gene (Latif
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FIGURE 1 | Comparison of the structures of SCF- and ECS-type
ubiquitin ligases. (A) SCF-type ubiquitin ligases. Cul1 is used as a scaffold
protein and Skp1 bridges the gap between the F box protein and Cul1.
(B) Cul2-type ubiquitin ligases. Cul2 is used as a scaffold protein and the
Elongin BC complex connects the VHL box protein to Cul2.The Cul2 box
determines the use of Cul2 as the scaffold protein. (C) Cul5-type ubiquitin
ligases. Cul5 is used as a scaffold protein. Note that the Rbx2 is used for
the recruitment of E2 enzyme.
et al.,1993). pVHL is the protein product of the VHL tumor sup-
pressor gene and can bind to the Elongin BC complex. Elongin A
and pVHL share a conserved Elongin C-binding sequence motif
(S,T,P)LXXX(C,S,A)XXXΦ,w h i c hi sr e f e r r e dt oa st h eB Cb o x
(Conaway et al., 1998; Mahrour et al., 2008). More than 70% of
VHL disease and sporadic clear cell renal carcinomas are caused
by mutation or deletion of the BC box, which reduces binding
afﬁnity to the Elongin BC complex (Duan et al., 1995; Kishida
et al.,1995).Approximately 57% of sporadic clear cell renal carci-
nomas contain inactivating mutations of VHL, of which 98% are
caused by loss of heterozygosity (LOH) at the VHL locus (Gnarra
et al., 1994). Epigenetic silencing of VHL by DNA methylation is
also involved in the inactivation of VHL (Herman et al., 1996).
Although pVHL inhibits the transcriptional activity of Elongin A
by competing for binding sites on the Elongin BC complex (Duan
et al., 1995), this review will focus on its ubiquitin ligase activity
rather than its affect on Elongin-mediated transcription. In addi-
tion to the Elongin BC complex, the VHL complex also contains
Cul2 and Rbx1 and is similar to SCF (Skp1–Cul1–F box protein)
type ubiquitin ligases (Figure 1; Kibel et al., 1995; Pause et al.,
1997; Kamura et al., 1999). In fact, the VHL complex has ubiq-
uitin ligase activity and targets the hypoxia-inducible factor-α
(HIF-α) family of transcription factors (HIF-1–3α) for protea-
somal degradation (Figure 2; Maxwell et al., 1999). At normal
oxygen levels, proline residues of the LXXLAP sequence motif
within the oxygen-dependent degradation domain (ODDD) of
HIF-α are hydroxylated and recognized by pVHL (Ivan et al.,
2001; Jaakkola et al., 2001; Masson et al., 2001; Hon et al., 2002).
As a result, HIF-α is polyubiquitinated and degraded. Three HIF
prolyl hydroxylases (PHD1–3) have been identiﬁed in mammals
and shown to hydroxylate HIF-α subunits (Epstein et al., 2001).
Since PHD2 is a critical enzyme for the hydroxylation of HIF-1α,
PHD1,and 3 may hydroxylate other target substrates (Berra et al.,
2003). In low oxygen conditions, PHDs are unable to hydroxy-
late the HIF-α subunits, which are therefore not recognized and
targeted for degradation by pVHL. The unhydroxylated HIF-α
dimerizes with constitutively expressed HIF-1β, also called aryl
hydrocarbon receptor nuclear translocator (ARNT), and translo-
cates to the nucleus, where it induces the transcription of down-
stream target genes, including vascular endothelial growth factor
A( VEGFA), solute carrier family 2 member 1 (SLC2A1, which
encodes GLUT1), and platelet-derived growth factor-β (PDGFB;
Kourembanas et al., 1990; Wizigmann-Voos et al., 1995; Gnarra
et al., 1996; Iliopoulos et al., 1996; Maxwell et al., 1999). Loss of
functional pVHL protein prevents the O2-dependent degradation
of HIF-α, resulting in constitutive expression of HIF-dependent
genes and consequentlyVHL disease.
The pVHL protein contains the recently deﬁned “VHL box,”
whichiscomposedof aBCboxandaCul2box(Figure3;Kamura
et al., 2004). The Cul2 box speciﬁcally recognizes the endogenous
Cul2/Rbx1 complex in a similar manner to SCF-type ubiquitin
ligase recognition by F box and Skp1 (Figure 1; Kamura et al.,
2004).TheringﬁngerproteinRbx1recruitsubiquitin-conjugating
enzymes and is an essential molecule for the formation of SCF-
type and Cul2-type ubiquitin ligases (Kamura et al., 1999, 2004;
Ohta et al., 1999; Seol et al., 1999; Skowyra et al., 1999; Tan et al.,
1999). Further study demonstrated that the Cul2 box is located
8–23aminoacidsC-terminaltotheBCboxandhastheconsensus
sequence ΦPXXΦXXXΦ, where the ﬁrst position is most fre-
quentlyaleucine(Mahrouretal.,2008).TheCul2boxistherefore
partially similar to the Cul5 box.
pVHL also polyubiquitinates and induces the degradation of
Sprouty2 (Spry2), which is implicated in the growth and pro-
gression of tumors (Anderson et al., 2011). Proline residues of
Spry2 are hydroxylated by PHD at normoxia and are recognized
bypVHLforpolyubiquitinationanddegradation(Andersonetal.,
2011). Epidermal growth factor receptor (EGFR) is also targeted
by pVHL for polyubiquitination and degradation (Zhou and
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FIGURE 2 | Regulation of HIF-α protein by pVHL. In normoxia, two
proline residues of HIF-α are hydroxylated by PHD1–3, and then HIF-α is
recognized by pVHL for polyubiquitination and degradation by the
proteasome. On the other hand, in hypoxia, HIF-α escapes prolyl
hydroxylation and thereby escapes degradation. HIF-α then dimerizes with
HIF-1β to form an active transcription complex. Prolonged activation of the
HIFα/β transcription complex is a major contributor to VHL disease.
Yang, 2011). pVHL is proposed to down-regulate tumor growth
causedbyprolongedsignalingof activatedEGFR(ZhouandYang,
2011). pVHL also mediates the polyubiquitination of the atyp-
ical PKCs, PKCλ, and PKCζII (Okuda et al., 2001; Iturrioz and
Parker, 2007). PKCζII interacts with Par6, which plays a critical
role in the development of tight junction structures and apico-
basal polarization. It also inhibits tight junction formation and
thereby plays a regulatory role in the development and trans-
formation of cell polarity (Suzuki et al., 2001; Parkinson et al.,
2004). PKCλ may have a similar function, which is also inhib-
ited by pVHL through ubiquitin-dependent degradation. pVHL
also polyubiquitinates the seventh subunit of human RNA poly-
merase II (hsRPB7) and suppresses hsRPB7-dependent VEGF
promoter transactivation, VEGF mRNA expression, and VEGF
proteinsecretion(Naetal.,2003).Thelargesubunitof RNApoly-




Rpb1 by UV radiation, which indicates that Rpb1 ubiquitination
may have a role in transcription-coupled DNA repair (Figure 4;
Svejstrup, 2002; Kuznetsova et al., 2003). Further study showed
that proline 1465 of Rpb1, which is located within the LXXLAP
motif, is hydroxylated mainly by PHD1 during oxidative stress
(Mikhaylova et al., 2008). pVHL is necessary for the oxidative
stress-dependent hydroxylation of Pro1465, the phosphorylation
of Ser5, and the polyubiquitination of Rpb1 and its recruitment
to the DNA (Mikhaylova et al., 2008). Surprisingly, in renal clear
cellcarcinoma(RCC),pVHLincreasedtheproteinabundanceand
non-degradativeubiquitinationofRpb1(Mikhaylovaetal.,2008).
Polyubiquitination of Rpb1 in RCC cells by pVHL contributes to
tumor growth by modulating gene expression (Mikhaylova et al.,
2008). This is different from previous results found in PC12 cells,
in which pVHL polyubiquitinates Rpb1 for protein degradation
(Kuznetsovaetal.,2003).HowpVHLdifferentiallyregulatesRpb1
in cells of different origins awaits further investigation.
CRL2LRR-1 COMPLEX
Leucine-rich repeat protein (LRR)-1 contains a VHL box and
physiologically interacts with the endogenous Cul2–Rbx1 com-
plex (Figure 3; Kamura et al., 2004; Costessi et al., 2011). In
fact, nematode LRR-1 degrades the Cip/Kip CDK-inhibitor CKI-
1i nC. elegans to promote cell cycle progression in germ cells
(Starostina et al., 2010). Human LRR-1 also polyubiquitinates
the CDK-inhibitor p21Cip1; however, it does not affect cell cycle
progression (Starostina et al., 2010). Rather, human LRR-1 tar-
gets cytoplasmic p21 for degradation to prevent the inhibi-
tion of the Rho/ROCK/LIMK pathway (Starostina et al., 2010).
These data indicate that human LRR-1 is a negative regulator
of coﬁlin, an actin-depolymerizing protein that decreases cell
motility (Starostina et al.,2010).
CRL2FEM1B COMPLEX
Feminization-1 (FEM-1) also contains aVHL box and physiolog-
ically interacts with endogenous Cul2–Rbx1 complex (Figure 3).
FEM-1 regulates apoptosis during the sex determination path-
way of the nematode (Hodgkin et al., 1985). In C. elegans, FEM-1
interacts with CED-4, an Apaf-1 homolog, to promote apoptosis,
suggestinganevolutionarilyconservedroleinapoptosisregulation
(Chan et al., 2000). Nematode FEM-1 polyubiquitinates TRA-1,
a Gli-family transcription factor and terminal effector of the sex




is highly enriched in mouse testis and is conserved from zebraﬁsh
to humans (Shi et al., 2011). These data indicate that the termi-
nal step in sex determination is controlled by ubiquitin-mediated
proteolysis.
Feminization-1 is polyubiquitinated by SEL-10, an F box
and WD40 repeat protein, for proteasomal degradation (Jager
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FIGURE 3 | Domain organization ofVHL box proteins. (A)The VHL box
consists of a BC box and a Cul2 box in the order indicated. LRR, leucine-rich
repeats; SWIMZ, SWI2/SNF2 MuDR zinc ﬁngers. (B) Alignment of amino acid
sequences of selected Cul2 boxes. Identical amino acids are highlighted in
yellow. GenBank™accession numbers of each protein are indicated.The
consensus sequence is indicated below. Φ, hydrophobic residue.
et al., 2004). In mammalian cells, receptor for activated C kinase
(RACK)1,alsoaWD40repeatprotein,associateswithFEM1Band
mediates the polyubiquitination and downregulation of FEM1B




RACK1 is a Cul2-type ubiquitin ligase (Liu et al., 2007).
CRL2PRAME COMPLEX
Preferentially expressed antigen of melanoma (PRAME) con-
tains a VHL box and physiologically interacts with endogenous
Cul2–Rbx1 complex (Kamura et al., 2004; Costessi et al.,
2011). Genome-wide chromatin immunoprecipitation experi-
ments revealed that PRAME is speciﬁcally enriched at enhancers
and at transcriptionally active promoters that are also bound by
nuclear transcription factorY (NFY),a transcription factor essen-
tial for early embryonic development (Bhattacharya et al., 2003;
Costessi et al., 2011). However, the physiological substrates of
PRAME have not yet been identiﬁed.
Cul5-TYPE UBIQUITIN LIGASE
CRL5Cis/SOCS COMPLEX
This family consists of suppressor of cytokine signaling
(SOCS) proteins and cytokine-inducible Src homology 2 (SH2)
domain-containing protein (CIS, also known as CISH), which
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also interacts with the Elongin BC complex through its SOCS box
(Piessevaux et al., 2008). To date, eight CIS/SOCS family proteins
havebeenidentiﬁed:CIS,SOCS1,SOCS2,SOCS3,SOCS4,SOCS5,
SOCS6,andSOCS7.Allof themhaveacentralSH2domainaswell
as a C-terminally located SOCS box consisting of a 40-amino acid
motif (Figure 5; Endo et al., 1997; Naka et al., 1997; Starr et al.,
1997). Members of the CIS/SOCS family bind to janus kinases
(JAKs),certaincytokinereceptors,orsignalingmolecules,thereby
suppressingdownstreamsignalingevents(Piessevauxetal.,2008).
A small kinase inhibitory region (KIR) of SOCS1 and SOCS3
inhibits the JAKs by acting as a pseudo-substrate, resulting in the
downregulation of further signal transduction (Piessevaux et al.,
2008). The CIS/SOCS family can also down-regulate signaling by
competing with downstream molecules for binding to the acti-
vated receptors (Ram and Waxman, 1999; Piessevaux et al., 2008)
and can prevent signaling by polyubiquitination and degrada-
tion of target substrates. For example, SOCS1 polyubiquitinates
JAK2, Vav, IRS1, and IRS2 (De Sepulveda et al., 2000; Kamizono
etal.,2001;Ruietal.,2002).Recentstudiesalsodemonstratedthat
SOCS1andSOCS3areimportantregulatorsofadaptiveimmunity
(Kile et al.,2002;Tamiya et al.,2011). Some SOCS box-containing
proteins – for example, CIS, SOCS1–7, SPRY domain-containing
SOCS box proteins (SSB1, SSB2, and SSB4, also known as SPSB1,
2, and 4, respectively), ras-related protein Rab-40C (also known
as RAR3), WD40 repeat-containing SOCS box protein WSB1,
leucine-rich repeat protein MUF1,and ankyrin repeat- and SOCS
box-containing protein (ASB)11 – also contain a BC box and
a Cul5 box inside the SOCS box (Figure 5; Hilton et al., 1998;
Kamuraetal.,2001,2004;Babonetal.,2009;SartoridaSilvaetal.,
2010). The amino acid sequence LPΦP in the Cul5 box results
in a speciﬁc interaction with Cul5, particularly when there is a
proline in the fourth position of the motif (Kamura et al., 2004).
Furthermore, endogenous Cul5 interacts with endogenous Rbx2,
enablingSOCSbox-containingproteinstoformaproteincomplex
with Cul5 and Rbx2 (Figure 1C; Kamura et al., 1999, 2004; Ohta
et al., 1999). The selective interactions between Cul2 and Rbx1
or Cul5 and Rbx2 suggest that Rbx1 and Rbx2 are functionally
distinct, at least in terms of their speciﬁc binding to Cullin family
members. Although SOCS1 contains a Cul5 box, no interaction
between SOCS1 and Cul5 has been detected, most likely because
theCul5boxisincompletelyconserved(Kamuraetal.,2004).Since
SOCS1polyubiquitinatesJAK2,Vav,IRS1,andIRS2(DeSepulveda
et al., 2000; Kamizono et al., 2001; Rui et al., 2002), it is possible
that the interaction of SOCS1 with these substrates recruits other
ubiquitin ligase(s) that actually mediate their polyubiquitination




to the rest of the family (Babon et al., 2009). In general, micro-
molar afﬁnities are common in physiological interactions, and
SOCS1 and SOCS3 have 1 and 0.1μM afﬁnities, respectively, for
Cul5(Babonetal.,2009).ThereforeitispossiblethatallCIS/SOCS
familymemberscanactasubiquitinligases.Thismayexplainwhy
only SOCS1 and SOCS3 have been shown to suppress signaling
using both SOCS box-dependent and -independent mechanisms
(Babon et al.,2009).
FIGURE 4 | Regulation of the large subunit of RNA polymerase II
(Rpb1) by pVHL and ElonginA. Ser5 and Pro1465 of Rpb1 are
phosphorylated and hydroxylated, respectively, by oxidative stress and then
recognized by the Cul2-type ubiquitin ligase pVHL.The resulting
polyubiquitinated Rpb1 is not degraded by proteasome and contributes to
tumor growth by modulating gene expression in renal clear cell carcinoma.
Ser5 of Rpb1 is also phosphorylated by UV irradiation and recognized by the
Cul5-type ubiquitin ligase Elongin A for proteasomal degradation.
CRL5Elongin A COMPLEX
pVHLisaubiquitinligaseforthelargesubunitofRNApolymerase
II (Rpb1), as mentioned above. Interestingly, ubiquitination and
proteasomal degradation of Rpb1 following UV irradiation are
signiﬁcantly suppressed in Elongin A-deﬁcient cells, which sug-
gests that Elongin A is also a ubiquitin ligase for Rpb1 (Yasukawa
et al., 2008). In fact, polyubiquitination and degradation are res-
cued by the transfection of wild-type Elongin A (Yasukawa et al.,
2008). Furthermore, Elongin A and the Elongin BC complex can
associate with Cul5 and Rbx2, and this complex efﬁciently polyu-
biquitinatesRpb1invitro(Yasukawaetal.,2008).Phosphorylation
of Rpb1 at Ser5 after UV irradiation signiﬁcantly enhanced the
interaction between Elongin A and Rpb1 (Yasukawa et al., 2008).
These data indicate that Elongin A, like pVHL, is involved in the
ubiquitination and degradation of Rpb1 following DNA damage
(Figure 4).
CRL5SSB COMPLEX
Inducible nitric oxide (NO) synthase (iNOS, NOS2) is a high-
output NOS compared with NOS1 and NOS3. The activity of
iNOS is approximately 10-fold greater than that of NOS1 and
NOS3 (Lowenstein and Padalko, 2004). iNOS is not expressed
under normal conditions but is induced in response to cytokines,
microbes, or microbial products, resulting in the sustained
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FIGURE 5 | Domain organization of SOCS box proteins. (A)The SOCS box
consists of a BC box and a Cul5 box in the order indicated. SH2, Src
homology 2 phosphotyrosine binding domain; WD40, WD40 repeats; SPRY,
sp1A/ryanodine receptor domain; Ank, ankyrin repeats; LRR, leucine-rich
repeats; GTPase, GTPase domain. (B) Alignment of amino acid sequences of
selected Cul5 boxes. Identical amino acids are highlighted in yellow.
GenBank™accession numbers of each protein are indicated.The consensus
sequence is indicated below. Φ, hydrophobic residue.
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production of NO (Lowenstein and Padalko, 2004). As a result,
reactive nitrogen intermediates (such as NO, nitrite, and nitrate)
and the products of the interaction of NO with reactive oxy-
gen species (such as peroxynitrite and peroxynitrous acid) are
accumulated and used to inhibit viruses or bacteria (Fang, 1997;
Nathan and Shiloh,2000; Lowenstein and Padalko,2004). SSB1,2
and4polyubiquitinateiNOSforproteasomaldegradation(Kuang
et al., 2010; Nishiya et al., 2011). SSB2-deﬁcient macrophages
showed prolonged iNOS and NO production, resulting in the
enhancedkillingof L.major parasites(Kuangetal.,2010).Further
study showed that SSB1 and SSB4 are major ubiquitin ligases for
iNOS and prevent the overproduction of NO, which could cause
cytotoxicity (Nishiya et al.,2011).
CRL5WSB1 COMPLEX
WSB1 polyubiquitinates homeodomain-interacting protein
kinase 2 (HIPK2), which is a nuclear protein kinase and is well-
conserved from Drosophila to humans (Choi et al., 2005, 2008).
HIPK2 interacts with a variety of transcription factors (D’Orazi
et al., 2002; Hofmann et al., 2002; Zhang et al., 2005; Kim et al.,
2006), the p300/CBP co-activator (Kim et al., 2002; Aikawa et al.,
2006), and the Groucho/TLE co-repressor (Choi et al., 2005).
The loss of HIPK2 reduces apoptosis and increases the numbers
of trigeminal ganglia, while the overexpression of HIPK2 in the
developing sensory and sympathetic neurons promotes apopto-
sis in a caspase-dependent manner (Doxakis et al., 2004; Wiggins
etal.,2004).HIPK2playsanimportantroleinapoptosismediated
by p53, CtBP, Axin, Brn3, Sp100, TP53INP1, and PML (Moller
et al., 2003a,b; Tomasini et al., 2003; Doxakis et al., 2004; Kanei-
Ishii et al., 2004). UV irradiation activates and stabilizes HIPK2,
most likely by WSB1-independent auto-phosphorylation, which
results in the phosphorylation of p53 at Ser46. Expression of
p53 target genes then promotes apoptosis (D’Orazi et al., 2002;
Hofmann et al., 2002). Genotoxic stresses, such as adriamycin
and cisplatin, also inhibit polyubiquitination of HIPK2 by WSB1
(Choi et al., 2008). HIPK2 also phosphorylates CtBP at Ser422
and phosphorylated CtBP is degraded via the 26S proteasome,
resulting in apoptosis in p53-deﬁcient cells (Zhang et al., 2003).
WSB1 expression is induced by Sonic hedgehog (Shh) in develop-
ing limb buds and other embryonic structures (Vasiliauskas et al.,
1999). WSB1 also ubiquitinates the thyroid hormone-activating
enzymetype2iodothyroninedeiodinase(D2;Denticeetal.,2005).
Ubiquitination of Shh-induced D2 by WSB1 induces parathyroid
hormone-related peptide (PTHrP), thereby regulating chondro-
cyte differentiation (Dentice et al., 2005). In addition to HIPK2
and D2, WSB1 also binds to the interleukin-21 receptor (IL-21R;
Nara et al.,2011). However,instead of promoting its degradation,
WSB1inhibitsthedegradationofthematureformofIL-21R(Nara
et al., 2011). WSB1 associates with the intracytoplasmic region of
IL-21R and enhances the maturation of IL-21R from an N-linked
glycosylated form to a fully glycosylated mature form (Nara et al.,
2011). These data indicate that WSB1 has important roles in both
the maturation and the degradation of IL-21R.
CRL5ASB COMPLEX
ASB2, 3, 4, 6, 9, and 11 can all bind to Cul5–Rbx2 and form
ubiquitin ligase complexes. Retinoic acid induces ASB2 in acute
promyelocytic leukemia cells (Guibal et al., 2002). ASB2 tar-
gets the actin-binding proteins ﬁlamin A and B for protea-
somal degradation (Heuze et al., 2008). Since knockdown of
endogenous ASB2 in leukemia cells delays retinoic acid-induced
differentiation and ﬁlamin degradation, ASB2 may regulate
hematopoietic cell differentiation by targeting ﬁlamins for degra-
dation and thereby modulating actin remodeling (Heuze et al.,
2008). ASB2 and Skp2 associate with each other to bridge the
formation of a non-canonical cullin1- and cullin5-containing
dimeric ubiquitin ligase complex and promote the polyubiqui-




ASB3 can affect T cell signaling by degrading TNF-R2, resulting
in the inhibition of downstream signaling events in response to
TNF-α (Chung et al., 2005).
Insulin receptor substrate 4 (IRS4) is an adaptor molecule
involved in signal transduction by both insulin and leptin, and is
widely expressed throughout the hypothalamus, with the greatest
expression observed in the medial preoptic nucleus,ventromedial
hypothalamus, and arcuate nucleus (Numan and Russell, 1999).
ASB4 co-localizes and interacts with IRS4 in hypothalamic neu-
rons(Lietal.,2011).ASB4polyubiquitinatesIRS4fordegradation
and decreases insulin signaling (Li et al.,2011).
ASB6 is expressed in 3T3-L1 adipocytes but not in ﬁbroblasts
(Wilcoxetal.,2004).ASB6mayregulatecomponentsoftheinsulin
signaling pathway in adipocytes by promoting the degradation
of adapter protein with a pleckstrin homology and SH2 domain
(APS;Wilcox et al.,2004).
ASB9 polyubiquitinates creatine kinase B (CKB) and decreases
total CKB levels (Debrincat et al.,2007).
Thenotchsignalingpathwayisessentialforthespatio-temporal
regulation of cell fate (Mumm and Kopan, 2000; Lai, 2004;
Louvi and Artavanis-Tsakonas, 2006). The single-pass trans-
membrane protein delta acts as a ligand for the notch recep-
tor. Danio rerio Asb11 (d-Asb11) regulates compartment size
in the endodermal and neuronal lineages via the ubiquitina-
tion and degradation of deltaA, leading to the activation of the
canonical notch pathway (Diks et al., 2006, 2008). This recog-
nition is speciﬁc to deltaA because d-Asb11 does not degrade
deltaD (Diks et al., 2008). In zebraﬁsh embryos, knockdown of
d-Asb11 repressed speciﬁc delta–notch elements and their tran-
scriptional targets, whereas these were induced when d-Asb11
was misexpressed (Diks et al., 2008). These data indicate that
d-Asb11 regulates delta–notch signaling for the ﬁne-tuning of lat-
eral inhibition gradients between deltaA and notch (Diks et al.,
2008).
CRL5RAB-40C COMPLEX AND CRLMUF1 COMPLEX
The substrates of Rab-40C and MUF1 have not yet been iden-
tiﬁed. However, Rab-40C localizes in the perinuclear recycling
compartment, suggesting its physiological role in receptor endo-
cytosis (Rodriguez-Gabin et al., 2004). Given that the mRNA and
protein level of Rab-40C increases as oligodendrocytes differenti-
ate, it may be important in myelin formation (Rodriguez-Gabin
et al.,2004).
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VIRAL ECS-TYPE UBIQUITIN LIGASE
CRL2HPV16E7 COMPLEX
Human papillomavirus (HPV) type 16 cause premalignant squa-
mous intraepithelial neoplasia (Munger et al., 2004). Integration
of viral DNA into the host genome leads to persistent and dys-
regulated expression of HPV E6 and E7 oncoproteins, which is
necessary for the induction and maintenance of the oncogenic
transformation (Munger et al., 2004). HPV E7 contains incom-
plete Cul2 box and can bind to endogenous Cul2 (Huh et al.,
2007). HPV E7 polyubiquitinates retinoblastoma tumor suppres-
sor(pRB)andinducesproteasomaldegradation(Boyeretal.,1996;
Berezutskaya et al., 1997; Jones and Munger, 1997; Huh et al.,
2007).
CRL5Vif COMPLEX
The viral infectivity factor (Vif) protein of human immunodeﬁ-
ciencyvirus-1(HIV-1)isalsoaCul5-typeubiquitinligase(Yuetal.,
2003;Bergeronetal.,2010).Importantly,ithasbeensuggestedthat
the zinc-binding motif of Vif is important for its interaction with
Cul5(Yuetal.,2004;Mehleetal.,2006;Xiaoetal.,2006).Vifpolyu-
biquitinates and degrades the cellular intrinsic restriction factors
APOBEC3F and APOBEC3G (Yu et al., 2003; Mehle et al., 2004;
Liu et al.,2005). BothAPOBEC3F and G have cytidine deaminase
activity and, when packaged into HIV-1 virions, cause uracil (U)
to be substituted for cytosine (C) in newly synthesized minus-
strandviralDNA(Sheehyetal.,2002;Harrisetal.,2003;Lecossier
et al., 2003; Mangeat et al., 2003; Mariani et al., 2003). The C-to-
U mutation introduced into minus-strand viral DNA results in
a guanine (G)-to-adenine (A) mutation in plus-strand viral DNA
becauseUisreadasTbyDNApolymerases(Lecossieretal.,2003).
These mutations cause amino acid substitutions, which affect the
enzymaticactivityof HIV-1(Harrisetal.,2003).Anotherpossibil-
ity is that deoxyuridine in minus-strand viral DNA is targeted for
excisionbyuracil-DNAglycosylase(Harrisetal.,2003).Theseaba-
sic sites are recognized and cleaved by endonucleases, inhibiting
HIV-1 replication (Harris et al.,2003). Since the CRL5Vif complex
targetsAPOBEC3FandAPOBEC3Gforproteasomaldegradation,




pVHL HIFα Ivan et al. (2001); Jaakkola et al. (2001);
Masson et al. (2001); Hon et al. (2002)
Spry2 Anderson et al. (2011)
EGFR Zhou andYang (2011)
Atypical PKC (PKCλ
and ζII)
Okuda et al. (2001); Iturrioz and Parker
(2007)
RPB7 Na et al. (2003)
Rpb1 Kuznetsova et al. (2003); Mikhaylova
et al. (2008)
LRR-1 CKI-1 (in C. elegans) Starostina et al. (2010)
p21Cip Starostina et al. (2010)
FEM1B TRA-1 Starostina et al. (2007)
Ankrd37 Shi et al. (2011)
itisapotentialtargetforthedevelopmentofantiviralagentsaimed
at preventing the interaction betweenVif and Cul5.
CRL5E4orf6 COMPLEX
The human adenovirus type 5 (Ad5) early region 4 34-kDa prod-
uct from open reading frame 6 (E4orf6) contains three BC boxes
(Blanchette et al., 2004; Cheng et al., 2007, 2011). Although Ad5
E4orf6 forms complex containing Cul5, Elongin BC complex,
and Rbx1, Cul5 box is not present in the Ad5 E4orf6 (Harada
et al., 2002; Blanchette et al., 2004; Cheng et al., 2011). Ade-
noviral protein E1B55K associates with the E4orf6 protein and
recognizes substrate to be degraded by ubiquitin–proteasome
pathway (Blanchette et al., 2004; Cheng et al., 2007; Luo et al.,
2007). This complex is essential for efﬁcient viral replication and
some substrates have been identiﬁed,including p53 (Moore et al.,
1996; Querido et al., 1997; Steegenga et al., 1998; Cathomen and
Weitzman, 2000; Nevels et al., 2000; Shen et al., 2001), meiotic
recombination 11 (Mre11; Stracker et al., 2002; Blanchette et al.,
2004), DNA ligase IV (Baker et al., 2007), integrin α3( Dallaire
et al.,2009),and adeno-associated virus type 5 (AAV5) Rep52 and






by pronounced radiosensitivity, genome instability, malignancy,
immunodeﬁciency, and bone marrow abnormalities (Chistiakov
etal.,2009).Heterodimerof integrinαandβsubunitsfunctionsas




laminins (DiPersio et al., 1995). E4orf6/E1B55K ligase complex is




SOCS1 JAK2 Kamizono et al. (2001)
Vav De Sepulveda et al. (2000)
IRS1 and IRS2 Rui et al. (2002)
ElonginA Rpb1 Yasukawa et al. (2008)
SSB1, 2, and 4 iNOS Kuang et al. (2010); Nishiya
et al. (2011)
WSB1 HIPK2 Choi et al. (2005, 2008)
D2 Dentice et al. (2005)
ASB2 Filamin A and B Heuze et al. (2008)
Jak3 Nie et al. (2011); Wu and
Sun (2011)
ASB3 TNF-R2 Chung et al. (2005)
ASB4 IRS4 Li et al. (2011)
ASB6 APS Wilcox et al. (2004)
ASB9 CKB Debrincat et al. (2007)
ASB11 DeltaA (in Danio rerio) Diks et al. (2006, 2008)
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Table 3 |Viral ECS-type ubiquitin ligases and corresponding substrates.
Viral ECS-type ubiquitin ligases Substrates References
HPV16E7 (Cul2-type) pRB Boyer et al. (1996); Berezutskaya et al. (1997); Jones and Munger (1997);
Huh et al. (2007)
Vif (Cul5-type) APOBEC3F and APOBEC3G Yu et al. (2003); Mehle et al. (2004); Liu et al. (2005)
E4orf6 of Ad5 (Cul5-type) p53 Moore et al. (1996); Querido et al. (1997); Steegenga et al. (1998);
Cathomen and Weitzman (2000); Nevels et al. (2000); Shen et al. (2001)
Mre11 Stracker et al. (2002); Blanchette et al. (2004)
DNA ligase IV Baker et al. (2007)
Integrin α3 Dallaire et al. (2009)
AAV5 Rep52 and capsid proteins Nayak et al. (2008)
E4orf6 of Ad16 (Cul2 and Cul5-type) DNA ligase IV Cheng et al. (2011)
BZLF1 (Cul2 and Cul5-type) p53 Sato et al. (2009a,b)
involved in cell detachment from the extracellular matrix, which
may contribute to virus spread (Dallaire et al., 2009). Although
Cul5 is present in the E4orf6 complex of the human Ad5, Cul2 is
primarilypresentintheE4orf6complexofAd12andAd40(Cheng
et al., 2011). Interestingly, E4orf6 complex of Ad16 binds Cul2 as
wellasCul5andisnotabletodegradep53andintegrinα3(Cheng
et al., 2011). It remains unclear how E4orf6 complexes of each
serotypes distinguish Cul2 from Cul5.
CRL5BZLF1 COMPLEX
Epstein–Barr virus (EBV), a human γ-herpesvirus, is associated
with several B cell and epithelial cell malignancies and there are
two different infection states, latent, and lytic (Tsurumi, 2001).
BZLF1 (known as Zta,EB1,or ZEBRA),is a transcriptional trans-
activator that induces EBV early gene expression to activate an
EBV lytic cycle cascade (Chevallier-Greco et al., 1986; Country-
manetal.,1987;HammerschmidtandSugden,1988;Sinclairetal.,
1991). BZLF1 can bind to Cul2 and Cul5 because of presence of
both Cul2 and Cul5 boxes (Sato et al., 2009a). BZLF1 polyubiq-
uitinates and induces degradation of p53 (Sato et al., 2009a,b).
The degradation of p53 prevents apoptosis and is required for the
efﬁcient viral propagation in the lytic replication.
CONCLUSION
The“classical”SOCS box proteins can be divided into two distinct
families.Cul2andCul5withintheVHLboxandSOCSbox,respec-
tively, determine the association with Rbx1 or Rbx2. Given that
Rbx1 and Rbx2 speciﬁcally interact with Cul2 and Cul5, respec-
tively, the functions of Rbx1 and Rbx2 are different from each
other,atleastinhighereukaryotes.Cul2-andCul5-typeubiquitin
ligases are structurally similar because they have the Elongin BC
complex adaptor protein and Cullin scaffold protein in common.
As with other ubiquitin ligases, these two have various substrates
and physiological functions (Tables 1, 2, and 3) and may have
arisen independently during evolution.
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